Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity.

Dhanasekaran R, Baylot V, Kim M, Kuruvilla S, Bellovin DI, Adeniji N, Rajan Kd A, Lai I, Gabay M, Tong L, Krishnan M, Park J, Hu T, Barbhuiya MA, Gentles AJ, Kannan K, Tran PT, Felsher DW.

Elife. 2020 Jan 14;9. pii: e50731. doi: 10.7554/eLife.50731.

2.

Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma.

Lai I, Swaminathan S, Baylot V, Mosley A, Dhanasekaran R, Gabay M, Felsher DW.

J Immunother Cancer. 2018 Nov 20;6(1):125. doi: 10.1186/s40425-018-0431-x.

3.

The MYC oncogene is a global regulator of the immune response.

Casey SC, Baylot V, Felsher DW.

Blood. 2018 May 3;131(18):2007-2015. doi: 10.1182/blood-2017-11-742577. Epub 2018 Mar 7. Review.

4.

Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC).

Dhanasekaran R, Gabay-Ryan M, Baylot V, Lai I, Mosley A, Huang X, Zabludoff S, Li J, Kaimal V, Karmali P, Felsher DW.

Oncotarget. 2017 Nov 9;9(5):5517-5528. doi: 10.18632/oncotarget.22342. eCollection 2018 Jan 19.

5.

TCTP Has a Crucial Role in the Different Stages of Prostate Cancer Malignant Progression.

Baylot V, Karaki S, Rocchi P.

Results Probl Cell Differ. 2017;64:255-261. doi: 10.1007/978-3-319-67591-6_13. Review.

PMID:
29149413
6.

Lipid-oligonucleotide conjugates improve cellular uptake and efficiency of TCTP-antisense in castration-resistant prostate cancer.

Karaki S, Benizri S, Mejías R, Baylot V, Branger N, Nguyen T, Vialet B, Oumzil K, Barthélémy P, Rocchi P.

J Control Release. 2017 Jul 28;258:1-9. doi: 10.1016/j.jconrel.2017.04.042. Epub 2017 May 1.

7.

MYC: Master Regulator of Immune Privilege.

Casey SC, Baylot V, Felsher DW.

Trends Immunol. 2017 Apr;38(4):298-305. doi: 10.1016/j.it.2017.01.002. Epub 2017 Feb 21. Review.

8.

Salmonella Typhimurium utilizes a T6SS-mediated antibacterial weapon to establish in the host gut.

Sana TG, Flaugnatti N, Lugo KA, Lam LH, Jacobson A, Baylot V, Durand E, Journet L, Cascales E, Monack DM.

Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):E5044-51. doi: 10.1073/pnas.1608858113. Epub 2016 Aug 8.

9.

MYC regulates the antitumor immune response through CD47 and PD-L1.

Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M, Felsher DW.

Science. 2016 Apr 8;352(6282):227-31. doi: 10.1126/science.aac9935. Epub 2016 Mar 10. Erratum in: Science. 2016 Apr 8;352(6282). pii: aaf7984. doi: 10.1126/science.aaf7984.

10.

The functional landscape of Hsp27 reveals new cellular processes such as DNA repair and alternative splicing and proposes novel anticancer targets.

Katsogiannou M, Andrieu C, Baylot V, Baudot A, Dusetti NJ, Gayet O, Finetti P, Garrido C, Birnbaum D, Bertucci F, Brun C, Rocchi P.

Mol Cell Proteomics. 2014 Dec;13(12):3585-601. doi: 10.1074/mcp.M114.041228. Epub 2014 Oct 2.

11.

TCTP as therapeutic target in cancers.

Acunzo J, Baylot V, So A, Rocchi P.

Cancer Treat Rev. 2014 Jul;40(6):760-9. doi: 10.1016/j.ctrv.2014.02.007. Epub 2014 Mar 2. Review.

PMID:
24650927
12.

Hsp27 as a therapeutic target in cancers.

Acunzo J, Andrieu C, Baylot V, So A, Rocchi P.

Curr Drug Targets. 2014 Apr;15(4):423-31. Review.

PMID:
24138636
13.

Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer.

Baylot V, Katsogiannou M, Andrieu C, Taieb D, Acunzo J, Giusiano S, Fazli L, Gleave M, Garrido C, Rocchi P.

Mol Ther. 2012 Dec;20(12):2244-56. doi: 10.1038/mt.2012.155. Epub 2012 Aug 14.

14.

TP53INP1 as new therapeutic target in castration-resistant prostate cancer.

Giusiano S, Baylot V, Andrieu C, Fazli L, Gleave M, Iovanna JL, Taranger-Charpin C, Garcia S, Rocchi P.

Prostate. 2012 Sep 1;72(12):1286-94. doi: 10.1002/pros.22477. Epub 2011 Dec 27.

PMID:
22213058
15.

OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer.

Baylot V, Andrieu C, Katsogiannou M, Taieb D, Garcia S, Giusiano S, Acunzo J, Iovanna J, Gleave M, Garrido C, Rocchi P.

Cell Death Dis. 2011 Oct 20;2:e221. doi: 10.1038/cddis.2011.104.

16.

Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.

Andrieu C, Taieb D, Baylot V, Ettinger S, Soubeyran P, De-Thonel A, Nelson C, Garrido C, So A, Fazli L, Bladou F, Gleave M, Iovanna JL, Rocchi P.

Oncogene. 2010 Apr 1;29(13):1883-96. doi: 10.1038/onc.2009.479. Epub 2010 Jan 18.

PMID:
20101233

Supplemental Content

Loading ...
Support Center